MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Quanterix Corporation Long-Term Debt 2011-2026 | QTRX
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Quanterix Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.3 M | 32.6 M | 37.2 M | 41.4 M | 20.5 M | 7.67 M | 7.59 M | 7.62 M | 4.35 M | 9.34 M | 7.65 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 41.4 M | 4.35 M | 18.7 M |
Quarterly Long-Term Debt Quanterix Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 496 K | 30.4 M | 31.5 M | 32.6 M | - | 35.1 M | 36.1 M | 37.2 M | 39.4 M | 40.4 M | 41.4 M | 42.2 M | 43.1 M | 43.6 M | 20.5 M | 1.94 M | 7.69 M | 7.69 M | 7.69 M | 1.91 M | 7.63 M | 7.61 M | 7.59 M | 7.59 M | 7.59 M | 7.59 M | 7.62 M | 7.62 M | 7.62 M | 7.62 M | 4.35 M | 4.35 M | 4.35 M | 4.35 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 43.6 M | 496 K | 18 M |
Long-Term Debt of other stocks in the Medical devices industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
88.2 M | $ 185.02 | -0.81 % | $ 13.9 B |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
71.3 M | - | - | $ 1.77 B | USA |
 |
Acutus Medical
AFIB
|
32.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Avinger
AVGR
|
1.1 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
7.56 M | - | - | $ 3.31 B | USA |
 |
AdaptHealth Corp.
AHCO
|
1.72 B | $ 12.58 | -0.55 % | $ 1.7 B | USA |
 |
Allied Healthcare Products
AHPI
|
2.93 K | - | 3.58 % | $ 2.21 M | USA |
 |
Aziyo Biologics
AZYO
|
3.59 M | - | 1.37 % | $ 20.5 M | USA |
 |
Bruker Corporation
BRKR
|
2.06 B | $ 38.94 | -1.37 % | $ 5.8 K | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
430 K | - | -5.86 % | $ 30.6 M | USA |
 |
BioSig Technologies
BSGM
|
103 K | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
20.6 M | - | - | $ 16.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
2.16 M | $ 3.59 | 1.99 % | $ 134 M |  France |
 |
Boston Scientific Corporation
BSX
|
11.1 B | $ 63.42 | -1.83 % | $ 93.9 B | USA |
 |
Apollo Endosurgery
APEN
|
34 M | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
1.33 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
16.7 M | $ 0.61 | 3.18 % | $ 38 M | USA |
 |
ClearPoint Neuro
CLPT
|
49.1 M | $ 10.5 | 0.38 % | $ 297 M | USA |
 |
Dynatronics Corporation
DYNT
|
1.11 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
11.9 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
1.1 M | $ 25.39 | -1.24 % | $ 215 M | USA |
 |
CryoLife, Inc.
CRY
|
290 M | - | -4.14 % | $ 702 M | USA |
 |
Second Sight Medical Products
EYES
|
17.1 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
1.65 M | - | -0.57 % | $ 7.12 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
154 K | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
38.6 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
7.64 M | - | - | $ 111 M |  Canada |
 |
Globus Medical
GMED
|
436 K | $ 92.76 | -1.87 % | $ 12.5 B | USA |
 |
Helius Medical Technologies
HSDT
|
12 K | $ 2.06 | 6.19 % | $ 1.25 M | USA |
 |
Butterfly Network
BFLY
|
20.4 M | $ 5.29 | 8.74 % | $ 1.12 B | USA |
 |
Intersect ENT, Inc.
XENT
|
63.6 M | - | - | $ 955 M | USA |
 |
Inogen
INGN
|
14.3 M | $ 6.59 | 6.29 % | $ 175 M | USA |
 |
IRIDEX Corporation
IRIX
|
98 K | $ 1.04 | - | $ 17.6 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
99.8 M | $ 16.53 | -7.39 % | $ 388 M | USA |
 |
BIOLASE
BIOL
|
11.8 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
835 K | $ 10.83 | -1.46 % | $ 388 M | USA |
 |
Inspire Medical Systems
INSP
|
30 M | $ 56.45 | -0.34 % | $ 1.66 B | USA |
 |
CONMED Corporation
CNMD
|
834 M | $ 37.91 | -3.88 % | $ 1.18 B | USA |
 |
LENSAR
LNSR
|
1.99 M | $ 5.8 | -7.2 % | $ 69.4 M | USA |
 |
LivaNova PLC
LIVN
|
345 M | $ 65.01 | -0.2 % | $ 3.55 B |  Britain |
 |
Integer Holdings Corporation
ITGR
|
1.19 B | $ 88.37 | 0.49 % | $ 3.07 B | USA |
 |
FONAR Corporation
FONR
|
155 K | $ 18.76 | -0.05 % | $ 123 M | USA |
 |
Invacare Corporation
IVC
|
354 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
598 M | $ 79.05 | 1.09 % | $ 46.2 B | USA |
 |
Penumbra
PEN
|
20.7 M | $ 331.47 | -0.29 % | $ 12.9 B | USA |
 |
Cutera
CUTR
|
1.06 M | - | -10.19 % | $ 1.99 M | USA |